SCHEMBL6946813

SCHEMBL6946813

COc1cc(OC)c(Oc2ccc3c(c2)OCO3)nc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
ALDH1A1 P00352 5/20 0.47
NOS2 P35228 2/20 0.45
MAPK1 P28482 2/20 0.44
KMT2A Q03164 4/20 0.43
MAPT P10636 3/20 0.43
TSHR P16473 2/20 0.43
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 3/20 0.41
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946624 0.77 NOS2 (0.62) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL6941366 0.76 LMNA (0.49) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL6947469 0.75 RAB9A (0.50) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL6944250 0.74 SMN1; SMN2 (0.49) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL6942398 0.72 NOS2 (0.51) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL746722 0.71 ALDH1A1 (0.56) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL30969590 0.71 KDR (0.59) KMT2AMEN1
SCHEMBL6165864 0.71 ALDH1A1 (0.78) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL6946833 0.70 ALDH1A1 (0.47) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL22162810 0.70 MEN1 (0.64) NPC1RAB9ASMN1; SMN2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 NPC1 1499/4885RAB9A 2017/4885SMN1; SMN2 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.